JP Morgan Chase
THRX

JP Morgan Chase’s Theseus Pharmaceuticals, Inc. Common Stock THRX Stock Holding History

JP Morgan Chase’s Portfolio THRX Stock Details THRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-14,052
Closed -$56.9K – 8071
2023
Q4 		$56.9K Buy
14,052
+911
+7% +$2.78K ﹤0.01% 5960
2023
Q3 		$35.3K Sell
13,141
-2,572
-16% -$10.1K ﹤0.01% 5913
2023
Q2 		$147K Buy
15,713
+2,676
+21% +$26.4K ﹤0.01% 5267
2023
Q1 		$116K Buy
13,037
+3,398
+35% +$33.4K ﹤0.01% 5359
2022
Q4 		$48K Buy
9,639
+480
+5% +$2.81K ﹤0.01% 5640
2022
Q3 		$53K Buy
9,159
+75
+0.8% +$530 ﹤0.01% 5534
2022
Q2 		$50K Buy
9,084
+3,687
+68% +$30.4K ﹤0.01% 5661
2022
Q1 		$62K Buy
5,397
+289
+6% +$3.09K ﹤0.01% 5711
2021
Q4 		$65K Buy
+5,108
New +$77.1K ﹤0.01% 5851

JP Morgan Chase's THRX Position: Q1 2024 in Review

JP Morgan Chase sold out of Theseus Pharmaceuticals, Inc. Common Stock (THRX) in Q1 2024, closing a stake of 14,052 shares — an estimated $56.9K sold.

JP Morgan Chase first reported a position in THRX in Q4 2021 and held it in 9 quarters. The position peaked at $147K in Q2 2023. 1 fund tracked by Wall St. Rank holds THRX as of Q1 2024.

  • JP Morgan Chase reported no remaining Theseus Pharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • JP Morgan Chase sold 14,052 Theseus Pharmaceuticals, Inc. Common Stock shares in Q1 2024, an estimated $56.9K.
  • JP Morgan Chase first reported a position in Theseus Pharmaceuticals, Inc. Common Stock in Q4 2021 and held it in 9 quarters.
  • JP Morgan Chase's Theseus Pharmaceuticals, Inc. Common Stock position peaked at $147K in Q2 2023.
  • 1 fund tracked by Wall St. Rank held Theseus Pharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on JP Morgan Chase's 13F filing for Q1 2024, filed 10 May 2024.